OncoSec Medical Inc (ONCSQ)

[readthechinastudy]

Thanks for your response, DrBob. I guess there are several ways of looking at this. However, it doesn't appear to me that Dr. Bhatia is "losing interest" in IL-12. In fact, IL-12 is mentioned earlier in his slide deck and he dedicates several slides to it, whereas TLR4 agonist is further down in the slide deck and only gets one line.

Regarding the web page you cited (http://www.merkelcell.org/news/), that IL-12 is listed further down on the page also doesn't suggest that Dr. Bhatia is losing interest in it. This page lists events chronologically and, because of this, the most recent events appear at the top. IL-12 is older than TLR4, so on a chronological list, it makes sense that IL-12 is listed further down on the list.

Additionally, you mentioned that TLR4 is being developed by a small company based in Seattle. If you're referring to Immune Design, the company is only first gearing up for a Phase 1 trial with TLR4, so we're about two years ahead of this company with IL-12.

I appreciate you mentioning your concern for IL-12 and encouraging me to look into TLR4. I'll have to keep my eye on it. But, in the meantime, I hope I helped to ease some of your concerns about IL-12.

GLTU